Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England.

Ueda P, Lung TW, Lu Y, Salomon JA, Rahimi K, Clarke P, Danaei G.

PLoS One. 2018 Mar 21;13(3):e0190688. doi: 10.1371/journal.pone.0190688. eCollection 2018.

2.

Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis.

Ueda P, Lung TW, Clarke P, Danaei G.

Br J Gen Pract. 2017 Sep;67(662):e598-e608. doi: 10.3399/bjgp17X692141. Epub 2017 Jul 31.

PMID:
28760741
3.

Photoexcited Properties of Tin Sulfide Nanosheet-Decorated ZnO Nanorod Heterostructures.

Liang YC, Lung TW, Xu NC.

Nanoscale Res Lett. 2017 Dec;12(1):258. doi: 10.1186/s11671-017-2022-z. Epub 2017 Apr 7.

4.

Erratum: EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation.

Pearson JS, Giogha C, Mühlen S, Nachbur U, Pham CL, Zhang Y, Hildebrand JM, Oates CV, Lung TW, Ingle D, Dagley LF, Bankovacki A, Petrie EJ, Schroeder GN, Crepin VF, Frankel G, Masters SL, Vince J, Murphy JM, Sunde M, Webb AI, Silke J, Hartland EL.

Nat Microbiol. 2017 Feb 13;2:17024. doi: 10.1038/nmicrobiol.2017.24. No abstract available.

5.

EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation.

Pearson JS, Giogha C, Mühlen S, Nachbur U, Pham CL, Zhang Y, Hildebrand JM, Oates CV, Lung TW, Ingle D, Dagley LF, Bankovacki A, Petrie EJ, Schroeder GN, Crepin VF, Frankel G, Masters SL, Vince J, Murphy JM, Sunde M, Webb AI, Silke J, Hartland EL.

Nat Microbiol. 2017 Jan 13;2:16258. doi: 10.1038/nmicrobiol.2016.258. Erratum in: Nat Microbiol. 2017 Feb 13;2:17024.

PMID:
28085133
6.

How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review.

Hua X, Lung TW, Palmer A, Si L, Herman WH, Clarke P.

Pharmacoeconomics. 2017 Mar;35(3):319-329. doi: 10.1007/s40273-016-0466-0. Review.

7.

Making guidelines for economic evaluations relevant to public health in Australia.

Lung TW, Muhunthan J, Laba TL, Shiell A, Milat A, Jan S.

Aust N Z J Public Health. 2016 Nov 20. doi: 10.1111/1753-6405.12601. [Epub ahead of print] No abstract available.

PMID:
27868297
8.
9.

Modelling obesity trends in Australia: unravelling the past and predicting the future.

Hayes AJ, Lung TW, Bauman A, Howard K.

Int J Obes (Lond). 2017 Jan;41(1):178-185. doi: 10.1038/ijo.2016.165. Epub 2016 Sep 27.

PMID:
27671035
10.

Growth of Hydrothermally Derived CdS-Based Nanostructures with Various Crystal Features and Photoactivated Properties.

Liang YC, Lung TW.

Nanoscale Res Lett. 2016 Dec;11(1):264. doi: 10.1186/s11671-016-1490-x. Epub 2016 May 23.

11.

Recent trends in life expectancy for people with type 1 diabetes in Sweden.

Petrie D, Lung TW, Rawshani A, Palmer AJ, Svensson AM, Eliasson B, Clarke P.

Diabetologia. 2016 Jun;59(6):1167-76. doi: 10.1007/s00125-016-3914-7. Epub 2016 Apr 5.

PMID:
27044338
12.

SseK3 Is a Salmonella Effector That Binds TRIM32 and Modulates the Host's NF-κB Signalling Activity.

Yang Z, Soderholm A, Lung TW, Giogha C, Hill MM, Brown NF, Hartland E, Teasdale RD.

PLoS One. 2015 Sep 22;10(9):e0138529. doi: 10.1371/journal.pone.0138529. eCollection 2015.

13.

Substrate recognition by the zinc metalloprotease effector NleC from enteropathogenic Escherichia coli.

Giogha C, Lung TW, Mühlen S, Pearson JS, Hartland EL.

Cell Microbiol. 2015 Dec;17(12):1766-78. doi: 10.1111/cmi.12469. Epub 2015 Jul 15.

PMID:
26096513
14.

A meta-analysis of the relative risk of mortality for type 1 diabetes patients compared to the general population: exploring temporal changes in relative mortality.

Lung TW, Hayes AJ, Herman WH, Si L, Palmer AJ, Clarke PM.

PLoS One. 2014 Nov 26;9(11):e113635. doi: 10.1371/journal.pone.0113635. eCollection 2014. Review.

15.

Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden.

Lung TW, Petrie D, Herman WH, Palmer AJ, Svensson AM, Eliasson B, Clarke PM.

Diabetes Care. 2014 Nov;37(11):2974-81. doi: 10.2337/dc14-0405. Epub 2014 Aug 4.

PMID:
25092684
16.

Inhibition of death receptor signaling by bacterial gut pathogens.

Giogha C, Lung TW, Pearson JS, Hartland EL.

Cytokine Growth Factor Rev. 2014 Apr;25(2):235-43. doi: 10.1016/j.cytogfr.2013.12.012. Epub 2013 Dec 25. Review.

PMID:
24440054
17.

A type III effector antagonizes death receptor signalling during bacterial gut infection.

Pearson JS, Giogha C, Ong SY, Kennedy CL, Kelly M, Robinson KS, Lung TW, Mansell A, Riedmaier P, Oates CV, Zaid A, Mühlen S, Crepin VF, Marches O, Ang CS, Williamson NA, O'Reilly LA, Bankovacki A, Nachbur U, Infusini G, Webb AI, Silke J, Strasser A, Frankel G, Hartland EL.

Nature. 2013 Sep 12;501(7466):247-51. doi: 10.1038/nature12524.

18.

Simulating lifetime outcomes associated with complications for people with type 1 diabetes.

Lung TW, Clarke PM, Hayes AJ, Stevens RJ, Farmer A.

Pharmacoeconomics. 2013 Jun;31(6):509-18. doi: 10.1007/s40273-013-0047-4.

PMID:
23585309
19.

Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.

Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ.

Diabetologia. 2013 May;56(5):973-84. doi: 10.1007/s00125-013-2856-6. Epub 2013 Mar 15. Review.

20.

Change in bias in self-reported body mass index in Australia between 1995 and 2008 and the evaluation of correction equations.

Hayes AJ, Clarke PM, Lung TW.

Popul Health Metr. 2011 Sep 25;9:53. doi: 10.1186/1478-7954-9-53.

21.

A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation.

Lung TW, Hayes AJ, Hayen A, Farmer A, Clarke PM.

Qual Life Res. 2011 Dec;20(10):1669-78. doi: 10.1007/s11136-011-9902-y. Epub 2011 Apr 7. Review.

PMID:
21472392

Supplemental Content

Support Center